A New Hepatitis C Treatment Costing $300 has 97 Percent Cure Rate
Sonia Canzater | Leave a Comment
The non-profit research team Drugs for Neglected Diseases Initiative (DNDI) announced that after a 12-week Clinical Trial conducted in Malaysia and Thailand involving new drug candidate ravidasvir and existing drug sofosbuvir showed that ravidasvir/sofosbuvir combination to be safe and effective with an extremely high cure rate.
The treatment is produced by Egyptian drug manufacturer Pharco Pharmaceuticals and costs approximately $3.50 a day. Both DNDI and Pharco hopes that this will provide a viable alternative to those who cannot afford the treatment.
For more information: see: https://www.msn.com/en-us/health/medical/24300-hepatitis-c-treatment-has-97-percent-cure-rate/ar-AAvO2xe and https://www.sciencedaily.com/releases/2018/04/180412085720.htm